Literature DB >> 10321019

P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells.

N M Maraldi1, N Zini, S Santi, K Scotlandi, M Serra, N Baldini.   

Abstract

Efflux of chemotherapy agents by P-glycoprotein at the plasma membrane is thought to be a major cause of cancer multidrug-resistance (MDR). However, the mechanism underlying the cellular accumulation and distribution of cytotoxic drugs is still poorly defined. We have recently found that P-glycoprotein is expressed also in the nucleus of MDR cell lines selected in doxorubicin (DXR), suggesting the possible involvement of this protein in the direct extrusion of the drug from the nucleus of resistant cells. In this study, we analyzed the subcellular localization of P-glycoprotein, in a series of U-2 OS osteosarcoma cell clones transfected with MDR1 gene in order to verify whether the nucleus is a constant site for the localization and functional activity of P-glycoprotein, and in which way some aspects of cell morphology related to MDR depend on the subcellular P-glycoprotein localization rather than on the exposure to the selective drug. Our results indicate that to achieve a subcellular drug distribution prevailing in the cytoplasm but not in the nucleus, a significant increase in the expression of P-glycoprotein at the different cellular compartments, including the plasma membrane, the cytoplasm, and the nucleus, is needed, although the in vitro drug resistance appears to be mainly dependent on the expression of P-glycoprotein at the cell surface. With regard to the morphological characteristics of MDR cells involving the cell surface and the chromatin arrangement, the influence of DXR appears to be prevalent, although P-glycoprotein overexpression cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321019

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  8 in total

1.  Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.

Authors:  Valérie Gouazé-Andersson; Jing Y Yu; Adam J Kreitenberg; Alicja Bielawska; Armando E Giuliano; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2007-11-09

2.  Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms.

Authors:  Sarah J Hemauer; Tatiana N Nanovskaya; Sherif Z Abdel-Rahman; Svetlana L Patrikeeva; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biochem Pharmacol       Date:  2009-11-06       Impact factor: 5.858

3.  P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.

Authors:  Tetsuo Yamagishi; Sumit Sahni; Danae M Sharp; Akanksha Arvind; Patric J Jansson; Des R Richardson
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

4.  P-Glycoprotein is not present in mitochondrial membranes.

Authors:  Jill K Paterson; Michael M Gottesman
Journal:  Exp Cell Res       Date:  2007-04-24       Impact factor: 3.905

5.  Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells.

Authors:  Xianlong Ling; Yuan Zhou; Shi-Wei Li; Bin Yan; Lei Wen
Journal:  Int J Biol Sci       Date:  2010-12-06       Impact factor: 6.580

6.  Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria.

Authors:  E A Roundhill; S A Burchill
Journal:  Br J Cancer       Date:  2012-02-21       Impact factor: 7.640

7.  Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT.

Authors:  E Roundhill; S Burchill
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 7.640

8.  Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.

Authors:  Yan-feng Song; Dao-zhou Liu; Ying Cheng; Miao Liu; Wei-liang Ye; Bang-le Zhang; Xin-you Liu; Si-yuan Zhou
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.